Market revenue in 2023 | USD 358.5 million |
Market revenue in 2030 | USD 536.0 million |
Growth rate | 5.9% (CAGR from 2023 to 2030) |
Largest segment | Cannabis/marijuana |
Fastest growing segment | Cannabis/Marijuana |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Alcohol, Cannabis/Marijuana, Cocaine, Opioids, Amphetamine & Methamphetamine, LSD, Other Drug Types |
Key market players worldwide | Quest Diagnostics Inc, Abbott Laboratories, Clinical Reference Laboratory, Cordant Health Solutions, ZeOmega, Psychemedics Corp, Millennium HealthCare Inc, Mayo Clinic, Precision Diagnostics, LGC Group, Labcorp Drug Development, Legacy Medical, Drugscan, USDTL |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to drug of abuse testing services market will help companies and investors design strategic landscapes.
Cannabis/marijuana was the largest segment with a revenue share of 24.27% in 2023. Horizon Databook has segmented the Canada drug of abuse testing services market based on alcohol, cannabis/marijuana, cocaine, opioids, amphetamine & methamphetamine, lsd, other drug types covering the revenue growth of each sub-segment from 2018 to 2030.
According to World Drug Report, published by the United Nations Office on Drugs and Crime (UNODC), in 2019, Canada reported the highest levels of cannabis use in North America. In 2017, 15% of the population, or 4.4 million people, aged 15 and older have used cannabis in the past year. Since 2015, the past-year use of cannabis among the general population in Canada increased by 25%.
According to the same source, in 2017, around 4,000 opioid-related deaths were reported in Canada, a 33% increase from the 3,000 overdose deaths reported in 2016. Around 69% of deaths were related to fentanyl or fentanyl analogs.
Furthermore, as per the Canadian Tobacco, Alcohol and Drugs Survey (CTADS), in 2017, around 2.5% of Canadians aged 15 and above reported using cocaine, a significant increase from the 0.9% who admitted to using in 2013.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada drug of abuse testing services market , including forecasts for subscribers. This country databook contains high-level insights into Canada drug of abuse testing services market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account